The evaluation of the clinical features of patients with non-Hodgkin lymphoma

Basit Öğe Kaydı
dc.authorscopusid35546856700
dc.authorscopusid23469279400
dc.authorscopusid8711887800
dc.authorscopusid6701664192
dc.authorscopusid15756259700
dc.authorscopusid7004457653
dc.authorscopusid7003486028
dc.contributor.authorPamuk G.E.
dc.contributor.authorHarmandar F.
dc.contributor.authorHarmandar O.
dc.contributor.authorTurgut B.
dc.contributor.authorTekgündüz E.
dc.contributor.authorDemir M.
dc.contributor.authorVural Ö.
dc.date.accessioned2024-06-12T10:29:24Z
dc.date.available2024-06-12T10:29:24Z
dc.date.issued2006
dc.description.abstractThe clinical features, histopathological types, treatment modalities and response, and survival analysis were evaluated in our 114 patients with non-Hodgkin lymphoma (NHL). At initial diagnosis, 10% had stage I, 14% stage II, 30% stage III, and 46% stage IV disease according to Cotswold classification. Therapy was administered to 101 (89%) NHL subjects at initial diagnosis. CHOP was given to 57 (56%) and rituximab (R)-CHOP to 17 (17%) cases. The highest rate of complete remission was in R-CHOP group (83%). The median survival of NHL subjects was 52 months. 3-year survival was 54%, 5-year survival was 46%. Survival of very aggressive lymphoma patients (3 months) was shorter than that of aggressive (41 months) and indolent (86 months) patients (p values<0.05). The median survival of stage IV subjects at initial diagnosis (26 months) was shorter than stage I (not reached), stage II (86 months) and stage III (96 months) cases (p values<0.05). Survival of patients with B symptoms, extranodal and bone marrow involvement, unresponsive to first-line therapy, IPI>2 at initial diagnosis was shorter than others (p values <0.05). Cox regression analysis showed that unresponsiveness to first-line therapy (OR:11.6, p=0.001) was an independent poor prognostic factor. It was interesting that combined chemotherapy with rituximab achieved a high rate of complete remission when given as first-line therapy.en_US
dc.identifier.endpage194en_US
dc.identifier.issn1306-133X
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-33845924705en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage185en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/17745
dc.identifier.volume16en_US
dc.indekslendigikaynakScopusen_US
dc.language.isotren_US
dc.relation.ispartofUHOD - Uluslararasi Hematoloji-Onkoloji Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChop; Non-Hodgkin Lymphoma; Prognosis; Rituximaben_US
dc.subjectCyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine; Adult; Aged; Article; Bone Marrow Metastasis; Cancer Chemotherapy; Cancer Regression; Cancer Staging; Cancer Survival; Clinical Evaluation; Clinical Feature; Controlled Study; Female; Histopathology; Human; Human Tissue; Major Clinical Study; Male; Nonhodgkin Lymphoma; Outcome Assessment; Primary Health Care; Prognosis; Proportional Hazards Model; Treatment Responseen_US
dc.titleThe evaluation of the clinical features of patients with non-Hodgkin lymphomaen_US
dc.title.alternativeNon-Hodgkin lenfoma vakalarimizin klinik özelliklerinin de?erlendirilmesien_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu